|
Re: Tykerb & Her2 signaling pathways explained
Rich--I agree with you regarding Tykerb. If I knew a year ago what I now know about the CNS risks of Her2+ disease and the limitations of Herceptin and advantages of Tykerb, I would have not been as afraid of the ALTTO Trial. Now, for early-stage me, it's too late for ALTTO and a chance at Tykerb, and I am locked out of the Neratinib Trial because of my gender. As they say, you live and learn, but really, living is more important.
bird
__________________
Male Breast Cancer, DX 5/15/09, IDC, STAGE 1, 1.7 cm, HER2+++, ER+(95%)/PR+(75%), Ki67 40%, grade 3, 0/5 nodes, TX: mastectomy, TCH finished 7/19/10, radiation 6 wks., Tamoxifen on going, bisphosphonate 24 mos.
|